Comparative Pharmacology
Head-to-head clinical analysis: DIDANOSINE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIDANOSINE versus EMTRICITABINE.
DIDANOSINE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that is converted to its active metabolite, dideoxyadenosine triphosphate (ddATP), which inhibits HIV reverse transcriptase and competes with the natural substrate dATP, leading to chain termination of viral DNA synthesis.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Weight-adjusted oral dose: 400 mg once daily (tablets) or 250 mg once daily (buffered powder) for adults ≥60 kg; 250 mg once daily (tablets) or 167 mg once daily (buffered powder) for adults <60 kg. Administer on an empty stomach (at least 30 minutes before or 2 hours after a meal).
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Clinical Note
moderateDidanosine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Atazanavir
"The serum concentration of Atazanavir can be decreased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Rilpivirine
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; prolonged to 4-8 hours in renal impairment.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose. Biliary/fecal elimination is minimal (<20%).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The serum concentration of Rilpivirine can be increased when it is combined with Didanosine."